Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−7.98%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

29.96 0.83 −2.70%
Market cap
$170.3B
P/E
42.2×
Fwd P/E
18.9×
Dividend yield
7.18%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

8.87% 8.28% 4.97% 4.42%
Piotroski F-Score
6 5 6 5
ROA
3.69% 3.60% 2.13% 1.95%
ROIC
6.45% 6.41% 6.30% 6.19%
Return on Tangible Assets
30.80% 26.87% 15.62% 12.48%
Average Days of Receivables
69.26 72.55 71.57 81.42
Free Cash Flow per Share
1.60 1.67 1.93 2.07
Free Cash Flow
9,075.00 9,483.00 10,985.00 11,786.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026